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Abstract
Background: Myocardial infarction is the combined result of environmental factors and personal
predispositions. Prothrombotic factors might play an important role in this phenomenon. Annexin
V (ANV) is a calcium-dependent glycoprotein widely present in various tissues exerting a potent
anticoagulant effect in vitro by reducing plaque adhesion and aggregation. Anti-annexin V antibodies
(aANVAs) are detected in various diseases like rheumatoid arthritis, systemic lupus erythematosus
and anti-phospholipid antibody syndrome. The study of ANV in Acute Myocardial Infarction (AMI)
might shed light on hypercoagulability mechanisms in the pathogenesis of acute coronary
syndromes. This study was conducted to investigate the association of plasma ANV, aANVAs and
anti-cardiolipin antibodies (aCLAs) with AMI.
Methods: This study recruited 45 patients with the diagnosis of AMI according to WHO criteria
in their first 24 hours of admission. 36 matched individuals were studied as the control group with
normal coronary artery angiography. Plasma levels of ANV, aANVAs and aCLAs were determined
by enzyme-linked immunosorbent assay and the results were compared.
Results: Plasma ANV levels in the patients with AMI on admission were significantly lower than
those in the control group (p = 0.002). Positive test for aANVAs were found to be present in a
significant number of our patients (p = 0.004). The studied groups were similar in their rate of
patients with positive aCLAs tests. ANV, aANVAs and aCLAs were not correlated with
hypertension, diabetes mellitus, hyperlipidemia, sex, age and smoking.
Conclusion: Our findings suggest that low plasma ANV levels along with positive aANVAs tests
in patients with AMI are indicative of hypercoagulable state that is not related to the traditional
cardiovascular risk factors.
Introduction
Myocardial infarction (MI) is the combined result of envi-
ronmental factors and personal predispositions [1]. Pro-
thrombotic factors may play a more important role in
these patients. Various prothrombotic factors and markers
of endothelial damage have been associated with an
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increased risk of myocardial infarction e.g. fibrinogen [2],
tissue plasminogen activator (t-PA) [2-4] and the von-Wil-
lebrand factor [2,3].
Annexin V (ANV) is a calcium-dependent glycoprotein
with a potent anticoagulant capacity in vitro [5] (mainly
as a result of its negatively charged membrane phosphol-
ipids), and capable of inhibiting the prothrombinase and
Tensa complexes to reduce plaque adhesion and aggrega-
tion [6]. Circulating ANV can be released from the cells of
the vascular wall (endothelial cells, smooth muscle cells)
or from secretor cells of the spleen and liver. Once it is in
the plasma, it binds to blood cells (platelets and erythro-
cytes) or to endothelial cells [7].
In addition, ANV possesses a high apoptotic cell affinity as
these cells produce a large amount of phospholipids, par-
ticularly phosphatydilserine [6]. ANV appears to form an
«antithrombotic shield» around the phospholipids, dis-
placing their coagulation factors [8]. Furthermore, ANV
has been shown to be an effective inhibitor of thrombus
formation in a venous and arterial thrombus model and
in vitro perfusion models. [9,10]. ANV binds to the phos-
phatidylserine inhibiting the pro-coagulant and pro-
inflammatory activities of the dying cell. It is considered
as an unspecific apoptosis marker [11].
The complex of phosphatidylserine and extracellular ANV
provides an antigenic stimulation for antibody produc-
tion. Anti-annexin V antibodies (aANVAs) were detected
in various abnormalities like rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE) [12-15], anti-phos-
pholipid antibody (APA) syndrome [16] and in cerebrov-
ascular disease [17].
This antibody has been associated with the occurrence of
thrombotic events and/or recurrent abortions in patients
with SLE and APA syndrome as well as digital ischemia in
patients with systemic sclerosis (SSc). Moreover, it is sus-
pected that aANVAs may interfere with annexin V func-
tion(s) and exert a detrimental role leading to thrombosis
and/or vascular occlusion [18]. It has been proposed that
APA syndrome may cause thrombotic events by means of
inhibition of ANV binding and resistance to ANV antico-
agulant activity [19].
ANV is widely used as a tool in apoptosis research [20],
but its physiological role has not been studied extensively
in relation to vascular biology. Few controversial studies
of aANVAs and acute coronary syndromes exist [20-22].
The investigation of ANV, aANVAs and anti-cardiolipin
antibodies (aCLAs) in MI might shed light on hypercoag-
ulability mechanisms in the pathogenesis of acute coro-
nary syndromes.
Our goal was to study the plasma level of ANV, aANVAs
and aCLAs in patients who developed acute myocardial
infarction, and to analyze their relationship with tradi-
tional cardiovascular risk factors.
Methods
Subjects
This case-control study recruited 45 consecutive patients
with acute myocardial infarction (AMI) including 31 men
and 14 women with the mean age of 62.7 ± 13.1 years old
who were taken to the emergency room of Peymanieh
Hospital (Jahrom, Iran) with the chief complaint of chest
pain from Feb 2007 to May 2008.
We also selected 36 individuals that referred to the emer-
gency room with chest pain with normal coronary angiog-
raphy as our control group and matched them for age, sex
and other CAD risk factors such as hypertension (HTN),
diabetes mellitus (DM) and hyperlipidemia (HLP).
The study protocol was approved by research ethics com-
mittee of Jahrom University of Medical Sciences and
informed consents were obtained from all participants
before enrollment.
A questionnaire including information about the past
medical and drug history (HTN, HLP, DM, smoking,
chronic diseases such as collagen vascular diseases and
asthma), family history of coronary artery disease (CAD)
and demographic information was completed for each
patient.
The exclusion criteria were the presence of severe liver dis-
ease, malignancy, recent cardiac surgery, angioplasty, sta-
ble or unstable angina, receiving of anticoagulant drugs,
hemolysis, pregnancy loss, history of deep vein or arterial
thrombosis, inflammatory and rheumatologic diseases
such as collagen vascular disease, SLE and APA syndrome.
Definitions
AMI was defined as chest pain lasting more than 30 min-
utes accompanied by ischemic electrocardiographic
changes and was confirmed by the presence of total creat-
inine phosphokinase (CPK) or MB fraction levels of more
than twice the upper normal limit [23,24]. The absence of
any narrowing in coronary artery diameter was considered
as normal coronary angiography.
Blood pressure was measured two times in sitting position
after 5 minutes of rest using a mercury sphygmomanom-
eter. Hypertension was defined as blood pressure more
than 130/85 mmHg or use of any antihypertensive medi-
cation [25]. DM was defined by a physician's diagnosis, a
fasting plasma glucose level of ≥126 mg/dl or use of dia-
betic medications [26]. Echocardiography was done for allThrombosis Journal 2009, 7:13 http://www.thrombosisjournal.com/content/7/1/13
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patients during their hospital stay by one cardiologist.
Ejection fraction (EF) is defined to be normal (>55%),
mild (45–54%), moderate (30–44%) and (>30%) severe
LV systolic dysfunction [27].
Laboratory analysis
Fasting levels of plasma total cholesterol, High density
lipoprotein (HDL) cholesterol, low density lipoprotein
cholesterol (LDL), and triglycerides (TG) were measured
in Research Laboratory of Jahrom Medical University.
Total cholesterol and triglyceride levels were measured by
enzymatic techniques using a Selectra E biochromatic
analyzer. HDL and LDL cholesterol level was measured
after glucose levels were measured by the glucose oxidase
method. CPK were measured by an enzymatic method.
Blood samples (5 cc) were obtained by venipuncture from
the patients immediately after admission before starting
any IV medications by trained staff and for lipid profile
and fasting blood sugar at the first 24 hours of AMI after
12 hours of fasting. In control subjects all blood sample
were obtained after 12 hours of fasting then plasma was
separated and frozen at -70°C for later processing. Level
of circulating annexin V and anti-annexin V and anti-car-
diolipin IgG antibodies were determined by enzyme
linked immunosorbent assay (ELISA) using high-sensitiv-
ity commercial kits (Aeskulisa, REF: 7204, Germany for
aCLAs, Bender Medsystems company, Cat. No.: BMS252,
Austria for annexin V and Medsystems Company, Cat.
No.: BMS247, Austria for aANVAs) according to manufac-
turer's recommendations.
The detection range for annexin V was indicated as0.2
to20 ng/mL. We consider aCLAs level above 15 ng/mL
and aANVAs level above1.18 ng/mL as positive results.
Statistical analysis
Statistical analysis was performed by SPSS (version 15;
SPSS, Inc., Chicago, IL). Data were expressed as mean ± 1
SD. Continuous variables with little-to-mild skewness
were summarized as mean ± SD and compared using Stu-
dent's t-test. Discrete variables were presented as frequen-
cies and group percentages. Nominal variables were tested
with Pearson's χ2 test and Binary variables were tested
with the chi square test. Pearson correlation coefficients
were calculated to evaluate unadjusted (univariate) asso-
ciations between ANV and other variables. Generalized
Linear Models were used to adjust smocking between two
groups. All tests were two-tailed with a 0.05 type I error
rate. ANOVA and Kruskal-Wallis test were used to evaluate
association of ANV, aANVAs and aCLAs with different
type of AMI and EF.
Results
The demographic and clinical characteristics of the study
groups, as well as laboratory variables are shown in Table
1. In patient group 6 cases (14%) had non-ST elevation MI
(NSTEMI) and 37 (86%) had ST elevation MI (STEMI).
There was no significant difference between the two
groups regarding the following variables: age, sex, pres-
ence of HTN, DM, LDL, HDL, total cholesterol and TG.
Plasma ANV levels in patients with AMI on admission
were significantly lower than those in the control group
(0.83 ± 0.77 ng/ml vs. 4.12 ± 2.88 ng/ml, p = 0.002) (Fig
1). Also, our patients had significantly more positive anti-
annexin V antibody results than the control group
[20(45.5%) vs. 6(15.8%), p = 0.004] (Fig 2) but no differ-
ence was found in the aCLAs test results between the two
groups (Table 1).
We examined the association between plasma ANV, aAN-
VAs and aCLAs and selected cardiovascular risk factors.
There was not a significant correlation between ANV and
the other two antibodies in patients and controls but we
found significant correlation between aANVAs and aCLAs
in patients (r = 0.69, p = 0.000) and controls (r = -0.91, p
= 0.000). Also, we didn't find a significant association
between plasma ANV, aANVAs and aCLAs with HTN,
Type 1 DM, Type 2 DM, age, sex, LDL, HDL, TG, total cho-
lesterol and adjusted smocking.
We didn't find a statically significant association of
plasma ANV, aANVAs and aCLAs with type of MI, LV
systolic function (EF) and mortality in our cases and with
sex and not with age in all subjects. Plasma ANV level in
patients with STEMI and those with NSTEMI were not sig-
nificantly different (0.75 ± 0.73 μg/ml vs. 1.35 ± 1.47 μg/
ml, p = 0.28).
Discussion
In the present case-control study, in line with previous
studies [21], we found that lower plasma ANV levels were
Plasma ANV in patients who had acute myocardial infarction  and in controls 0.83 ± 0.77 ng/ml vs 4.12 ± 2.88 ng/ml; p =  0.002 Figure 1
Plasma ANV in patients who had acute myocardial 
infarction and in controls 0.83 ± 0.77 ng/ml vs 4.12 ± 
2.88 ng/ml; p = 0.002.
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associated with AMI among Iranian patients independent
of traditional cardiovascular risk factors.
Like our findings, Roldan et al [21] found lower ANV in
patients with old MI in comparison with normal subjects
being in contrast to others that showed higher than con-
trols levels [20] or reporting levels to be within normal
limits [22]. Roldan's study also found that ANV is not cor-
related with traditional atherosclerotic risk factors. [21]
But Oleu [28] considered ANV as a risk factor of prema-
ture MI. All that studied patients were under 50 years old
which is not comparable to our study.
Cederholm et al [20] showed a significantly higher level of
circulating ANV in SLE cases with history of Cerebrovascu-
lar Disease (CVD) compared to SLE controls and normal
population. This rise could be a result of ANV displace-
ment and/or raised production. Although little is known
about the role of circulating ANV it would be possible that
ANV contributes to growth of atherosclerotic plaques at a
late stage of disease, in which apoptosis, fissures, and
microthrombi, as well as endothelial cell activation are
common features of the plaque complex facilitating ANV
binding to the exposed surfaces. In a previous elegant
study, it was demonstrated that arterial thrombosis could
be inhibited by recombinant ANV in a rabbit model of
carotid artery injury [29].
Kaneko et al [22] and Matsudo et al [30] in two separate
studies showed early elevation in plasma ANV levels in
the first 6 hour of AMI and a subsequent decrement. They
could not provide a clear explanation of this observation.
In contrast, we found lower ANV levels in our patients.
This discrepancy might be a result of auto antibodies
against ANV, displacement of ANV by aCLAs [20], selec-
tive ANV binding to the thrombi [31], race differences
and/or hypercoagulable states in our patients.
Matsudo and his colleagues [30] found association of
AVN levels with prognosis but in our study, we could not
find any association between ANV and type of MI, EF and
mortality. It seems that ANV could be better considered as
a marker of apoptosis. An anecdotal study by Kaneko and
Positive anti-ANV antibodies in patients who had an acute  myocardial infarction and in controls, 20(45.5%) vs. 6(15.8%),  p = 0.004 Figure 2
Positive anti-ANV antibodies in patients who had an 
acute myocardial infarction and in controls, 
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Table 1: Demographic and clinical characteristics of the study groups
Variable Case group
n = 45
Control group
n = 36
P-value
Age 62.7 ± 13 60.1 ± 11.9 0.38
Male, n (%) 31 (68.9%) 18 (50%) 0.08
Current smoker, n(%) 11 (24.4%) 2 (5.6%) 0.02 *
HTN, n(%) 8 (17.8%) 11 (30.6%) 0.18
Type 1 DM, n (%) 2 (4.4%) 4(11.1%) 0.4
Type 2 DM, n (%) 7(5.6%) 4(11.1%) 0.56
Total Cholesterol (mg/dL) 189.2 ± 43.7 176.3 ± 32.3 0.14
LDL-C (mg/dL) 112.8 ± 35.6 106 ± 28.7 0.36
HDL-C (mg/dL) 46.2 ± 11.4 42.3 ± 10 0.11
LDL/HDL ratio 4.23 4.24 0.96
Triglyceride (mg/dL) 146.1 ± 97.6 153 ± 105.5 0.76
ANV (ng/mL) 0.84 ± 0.93 4.12 ± 2.88 0.003*
aANVAs(ng/mL) 33.2 ± 55 17.8 ± 54.4 0.2
Positive aANVAs 20(45.5%) 6(15.8%) 0.004*
aCLAs(ng/mL) 21.7 ± 55.7 13.9 ± 38.1 0.46
Positive aCLAs 8(18.6%) 5(13.2%) 0.53
HTN: hypertension, LDL-C: low density lipoprotein-cholesterol, HDL-C: high density lipoprotein-cholesterol, ANV: annexin V, aANVAs: anti 
annexin V antibodies, aCLAs: anti cardiolipin antibodies
Values are presented as mean ± SD or %.Thrombosis Journal 2009, 7:13 http://www.thrombosisjournal.com/content/7/1/13
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his coworkers [22] concluded that ANV is a diagnostic test
for AMI but much evidence including ours is to the con-
trary of such an assumption.
It has been proposed that ANV could play an essential role
in the thrombogenic mechanisms of APAs [32]. IgG frac-
tions in patients with APA reduce the ANV levels in tro-
phoblastic and endothelial cell cultures [8], resulting in
an increase in the amount of anionic phospholipids capa-
ble of initiating coagulation [5]. It is known that APA is
associated with hypercoagulability states [33]. IgG frac-
tion from APA patients lowers ANV on non cellular phos-
pholipid surfaces and accelerates plasma coagulation
following thrombin generation [19,34]. In our study no
correlation was found between APA and AMI but we
found strong correlations between aCLAs and aANVAs.
A remarkable clinical finding in our study was the number
of positive aANVAs results. In Roldan's study [21] only
two patients with positive aANVAs were found but in our
study about 45.5% of patients had positive aANVAs being
the first study to identify such a high incidence in AMI.
These discrepancies may be due to they detected anti ANV
IgG only but we detected all antibody subtypes against
annexin V and also race differences. Mechanisms raising
aANVAs are not completely elucidated but it is proposed
that in the context of increased apoptosis, extracellular/
membrane ANV might become an antigenic stimulus for
specific antibody production [17]. Such antibodies may
have a detrimental role interfering with putative functions
of ANV [35]. Since there is a lag or latent phase between
the initial exposure to an immunogen and detection of
antibodies in the circulation, which several days average
about 1 week in human [36] and we got our samples in
the first day of AMI, it could be concluded that aANVAs
have been present in our patients before MI occurrence
and are not secondary to it.
The occurrence of auto antibodies to ANV has been
described in several pathological disorders encompassing
thrombosis mechanisms. For example, aANVAs concen-
trations are raised significantly in sera of RA patients com-
pared to normal controls [15]. Sugiura and Muro [37]
showed that aANVAs correlates with the occurrence of dig-
ital ischemia in SSc patients. Thrombosis is increased in
APA patients with aANVAs positive [16]. Kaburaki and
colleagues [38] found a correlation between the detection
of aANVAs and clinical presentations of arterial and/or
venous thrombosis, intra-uterine fetal loss and prolonged
activated partial thromboplastin time in SLE patients.
In our study, serum ANV level, aANVAs and aCLAs were
measured in a single sample. We couldn't followed the
patients prospectively and perhaps a prospective cohort
study for ANV and aANVAs levels would become more
narrative as the next step to elucidate their portray. Gasp-
ersic N et al [39] showed competition of anti-β2 glycopro-
tein I with ANV for binding to phospholipid but we didn't
analyze the presence of anti-β2 glycoprotein I in patients.
Conclusion
We showed, for the first time, the high incidence of aAN-
VAs in AMI. Our findings further support the notion that
ANV has antithrombotic properties. Our data suggest that
the low plasma ANV together with high level of aANVAs
in patients with AMI may indicate the existence of a hyper-
coagulable state that does not appear to be related to the
traditional cardiovascular risk factors.
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